The reported elevated levels of syndecan-1 in the cerebrospinal fluid of MS patients may potentially indicate either a protective role where syndecan-1 expression is upregulated in response to pathological conditions or its neurotoxic role in which syndecan-1 signaling contributes to disease progression [164]. Here, SDC1 is linked to myeloid sarcoma.